Vor Biopharma Files 8-K with Updates

Ticker: VOR · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1817229

Vor Biopharma Inc. 8-K Filing Summary
FieldDetail
CompanyVor Biopharma Inc. (VOR)
Form Type8-K
Filed DateSep 5, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory

TL;DR

Vor Bio filed an 8-K on 9/5/24 with regulatory disclosures and financial updates.

AI Summary

Vor Biopharma Inc. filed an 8-K on September 5, 2024, reporting on events including a Regulation FD Disclosure and Other Events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.

Why It Matters

This 8-K filing provides important updates and disclosures from Vor Biopharma Inc. to investors and the public.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not appear to contain significant negative news or events.

Key Numbers

  • 001-39979 — Commission File Number (Identifies Vor Biopharma Inc. in SEC filings.)

Key Players & Entities

  • Vor Biopharma Inc. (company) — Registrant
  • September 5, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • Cambridge, Massachusetts (location) — Address of Principal Executive Offices
  • 001-39979 (company_id) — Commission File Number

FAQ

What specific events are disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure but does not detail the specific events within the provided text.

What is the nature of the 'Other Events' reported?

The filing lists 'Other Events' as a category but does not specify the details of these events in the provided excerpt.

When was Vor Biopharma Inc. incorporated?

Vor Biopharma Inc. was incorporated in Delaware.

What is the principal executive office address?

The principal executive offices are located at 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts, 02140.

What is the filing date of this 8-K?

This 8-K was filed on September 5, 2024.

Filing Stats: 1,427 words · 6 min read · ~5 pages · Grade level 15.1 · Accepted 2024-09-05 16:06:04

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "aim," "anticipate," "can," "continue," "could," "design," "enable," "expect," "initiate," "intend," "may," "on-track," "ongoing," "plan," "potential," "should," "target," "update," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Current Report on Form 8-K include Vor Bio's statements regarding the potential of its product candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat, the timing of regulatory filings and initiation of clinical trials, the timing and pace of patient enrollment and dosing in clinical trials and the availability of data therefrom, the expected safety profile of its product candidates, its intentions to use VCAR33 ALLO in combination with trem-cel as a Treatment System, the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts, and the ability of VADC45 to treat hematologic malignancies and to be used as a targeted conditioning agent for gene therapies, as a holistic immune reset for autoimmune disorders, and in combination with opitope modification of CD45 to shield healthy stem cells. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development o

Financial Statements and Exhibits

Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release, dated September 5, 2024 99.2 Corporate Presentation, dated September 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. Date: September 5, 2024 By: /s/ Robert Ang Robert Ang Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.